Sino Biological/IGFBP-3 Protein, Human, Recombinant (His Tag)/1/10430-H07H
商品编号：
10430-H07H
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
IGFBP-3 Protein, Human, Recombinant (His Tag): Product Information
Purity
> 85 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
1. Measured by its binding ability in a functional ELISA. Immobilized human IGF2 (Cat:13032-H24E) at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 18 ng/mL.2. Measured by its binding ability in a functional ELISA. Immobilized human IGF1 (Cat:10598-H24E) at 10 μg/mL (100 μl/well) can bind biotinylated Human His-IGFBP3, The EC50 of biotinylated Human His-IGFBP3 is 24 ng/mL.3. Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.). The ED50 for this effect is typically 0.02-0.2 μg/mL in the presence of 14 ng/mL human IGFII.
Protein Construction
A DNA sequence encoding the mature form of human IGFBP3 (NP_000589.2) (Gly28-Lys291) was fused with a polyhistidine tag at the N-terminus.
Accession#
NP_000589.2
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
His
Molecule Mass
The secreted recombinant human IGFBP3 comprises 280 amino acids with a predicted molecular mass of 31 kDa. As a result of glycosylation, the apparent molecular mass of rhIGFBP3 is approximately 40-45 kDa in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
IGFBP-3 Protein, Human, Recombinant (His Tag): Images
Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.). The ED50 for this effect is typically 0.02-0.2 μg/mL in the presence of 14 ng/mL human IGFII.
IGFBP-3 Protein, Human, Recombinant (His Tag): Synonyms
BP-53 Protein, Human; IBP3 Protein, Human; IGFBP3 Protein, Human
IGFBP-3 Background Information
The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation, and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and is a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signaling appears to require an active transforming growth factor-beta (TGF-beta) signaling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signaling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR)-alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.
Full Name
insulin-like growth factor binding protein 3
References
- Baxter RC. (2001) Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 54(3): 145-8.
- Butt AJ, et al. (2001) IGFBP-3 and apoptosis--a license to kill? Apoptosis. 6(3): 199-205.
- Ali O, et al. (2003) Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res. 35(11-12): 726-33.
- Yamada PM, et al. (2009) Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 296(5): C954-76.
Cynomolgus IGFBP-3 Proteins
- IGFBP-3 Protein, Cynomolgus, Recombinant (His Tag)90084-C07H
- Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cellsAuthorWu, YC;Zhu, M;Robertson, DM;Year2012JournalPLoS ONEApplicationcell-based (proliferation)PubMed ID: 22879999FoldedExpand
- Mutual regulation between IGF-1R and IGFBP-3 in human corneal epithelial cellsAuthorTitone, R;Zhu, M;Robertson, DM;Year2018JournalJ. Cell. Physiol.Applicationcell-basedPubMed ID: 30078228FoldedExpand
- Validation of a multiplexed LC-MS/MS clinical assay to quantify insulin growth factor binding proteins in human serum and its application in a clinical studyAuthorLiu, N;Tengstrand, E;Boernsen, O;Bek, S;Hsieh, F;Year2019JournalToxicol. Appl. Pharmacol.Applicationassay validationPubMed ID: 30926377FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
